MK-4280A-008
A Study of Coformulated Favezelimab/Pembrolizumab Versus Physician’s Choice Chemotherapy in PD-1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma
Completed
Trial purpose
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth). Researchers want to learn if people who receive coformulated favezelimab/pembrolizumab (MK-4280A) live longer without the cancer getting worse compared to those who receive chemotherapy.
View full trial information on Clinicaltrials.govNATIONAL TRIAL REFERENCE NUMBER
NCT05508867
When you talk with your doctor or clinical trial team member, please have the national trial reference number available.
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Hodgkin Lymphoma
Age Range
18+
Sex
Male/Female
Current trial Phase
Phase 2
Tests the medicine or vaccine in approximately 100 to 500 participants. In the case of medicines, participants usually have the disease or condition the investigational medicine is designed to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial start and end dates
- Trial start date 10-18-2022
- Estimated primary completion date 09-03-2025
- Estimated trial completion date 01-08-2026
Trial Locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.